pdf
Published
2022-03-29
Issue
Section
Pharmacy Practice & Practice-Based Research
Categories
License
Copyright (c) 2022 Kelsey Mews, Audrey Umbreit, Emily Holm, Kelsie Davis, Ellen Kelly, Carson Reinhardt, Allison Young, Joseph Flynn
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
Impact of a Pharmacist-Led Warfarin to Direct Oral Anticoagulant Conversion Initiative during the COVID-19 Pandemic
Kelsey Mews
Mayo Clinic Health System
Audrey Umbreit
Mayo Clinic Health System
Emily Holm
Mayo Clinic Health System
Kelsie Davis
Mayo Clinic Health System
Ellen Kelly
Mayo Clinic Health System
Carson Reinhardt
Mayo Clinic Health System
Allison Young
Mayo Clinic Health System
Joseph Flynn
Mayo Clinic Health System
DOI: https://doi.org/10.24926/iip.v13i1.4491
Keywords: DOAC, COVID-19, anticoagulation
Abstract
Purpose: To assess the impact of a pharmacist-led warfarin to DOAC conversion initiative during the COVID-19 pandemic.
Methods: Patients who were prescribed warfarin and followed with the anticoagulation clinic for INR monitoring were assessed by outpatient clinical pharmacists as potential candidates for transition to DOACs from March-August 2020.
Results: 530 patients were assessed for transition to DOACs, of which 373 (70.4%) were deemed by clinical pharmacists to be candidates for DOACs. Of the patients who were candidates for DOACs, 66 (17.7%) were transitioned from warfarin to a DOAC. Of the patients who transitioned to a DOAC, 59 (89.4%) remained on a DOAC after one year.
Conclusion: Outpatient clinical pharmacists are an effective resource to help identify patients who are candidates for DOACs and assist with transition from warfarin. Further, high persistence rates with DOAC therapy after one year demonstrate the positive impact of the clinical pharmacist on medication adherence.
